Skip to main content
Top
Published in: Archives of Dermatological Research 3/2023

23-07-2022 | General Dermatology | Original Paper

Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study

Authors: Khalaf Kridin, Kailyn Valido, Jeffrey M. Cohen, Arnon D. Cohen

Published in: Archives of Dermatological Research | Issue 3/2023

Login to get access

Abstract

Previous studies have identified an association between myocardial infarction (MI), cerebrovascular accident (CVA), and peripheral vascular disease (PVD) in patients with hidradenitis suppurativa (HS). To evaluate the risk and prognostic outcomes of MI, CVA, and PVD in patients with HS. A population-based retrospective cohort study using the computerized database of Clalit Health Services (CHS), the largest managed care organization in Israel, was conducted to compare the incidence of MI, CVA, and PVD among patients with HS (N = 6779) with age-, sex- and ethnicity-matched control subjects (N = 33,260). Adjusted hazard ratios (HRs) were estimated by multivariate Cox regression analysis. The overall incidence rates of MI, CVA, and PVD were estimated at 2.9 (2.3–3.4), 1.3 (0.9–1.7), and 0.8 (0.6–1.1) per 1000 person-year, respectively. Patients with HS were at an increased risk of developing MI (fully-adjusted HR 1.33; 95% CI 1.04–1.68; P = 0.021), but the risk of CVA (fully-adjusted HR 0.82; 95% CI 0.59–1.14; P = 0.245) and PVD (fully-adjusted HR 1.22; 95% CI 0.80–1.87; P = 0.355) was comparable relative to controls. Compared to other patients with HS, increased risk of all-cause mortality was observed among patients with HS and comorbid MI (HR 12.56; 95% CI 7.59–20.80; P < 0.001), CVA (HR 13.33; 95% CI 7.29–24.37; P < 0.001), and PVD (HR 7.11; 95% CI 2.61–19.32; P < 0.001). Patients with HS are at an increased risk of MI, but not CVA and PVD. Awareness of these epidemiological findings is of importance for clinicians managing patients with HS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644CrossRefPubMed Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644CrossRefPubMed
2.
go back to reference Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol 11(10):17–23PubMedPubMedCentral Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol 11(10):17–23PubMedPubMedCentral
3.
go back to reference Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032CrossRefPubMed Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032CrossRefPubMed
4.
5.
go back to reference Ballard K, Shuman VL (2021) Hidradenitis suppurativa. In: StatPearls. Treasure Island, FL. Ballard K, Shuman VL (2021) Hidradenitis suppurativa. In: StatPearls. Treasure Island, FL.
6.
go back to reference Nguyen TV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35(1):50–61CrossRefPubMed Nguyen TV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35(1):50–61CrossRefPubMed
7.
go back to reference Lyons AB et al (2020) Emerging medical treatments for hidradenitis suppurativa. J Am Acad Dermatol 83(2):554–562CrossRefPubMed Lyons AB et al (2020) Emerging medical treatments for hidradenitis suppurativa. J Am Acad Dermatol 83(2):554–562CrossRefPubMed
8.
go back to reference Casseres RG et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524–1526CrossRefPubMed Casseres RG et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524–1526CrossRefPubMed
9.
go back to reference Prussick L et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609–611CrossRefPubMed Prussick L et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609–611CrossRefPubMed
10.
go back to reference Rosales Santillan M et al (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 20(6):621–633CrossRefPubMed Rosales Santillan M et al (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 20(6):621–633CrossRefPubMed
11.
go back to reference Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434CrossRefPubMed Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434CrossRefPubMed
12.
go back to reference Miller IM, McAndrew RJ, Hamzavi I (2016) Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin 34(1):7–16CrossRefPubMed Miller IM, McAndrew RJ, Hamzavi I (2016) Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin 34(1):7–16CrossRefPubMed
14.
go back to reference Keary E, Hevey D, Tobin AM (2020) A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol 182(2):342–347CrossRefPubMed Keary E, Hevey D, Tobin AM (2020) A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol 182(2):342–347CrossRefPubMed
15.
go back to reference Shavit E et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(2):371–376CrossRefPubMed Shavit E et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(2):371–376CrossRefPubMed
17.
go back to reference Miller IM et al (2018) Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol 178(3):790–791CrossRefPubMed Miller IM et al (2018) Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol 178(3):790–791CrossRefPubMed
18.
go back to reference Cohen AD et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149(4):204–209PubMed Cohen AD et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149(4):204–209PubMed
19.
go back to reference Tzellos T et al (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142–1155CrossRefPubMed Tzellos T et al (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142–1155CrossRefPubMed
20.
go back to reference Pascual JC et al (2017) Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31(7):1229–1238CrossRefPubMed Pascual JC et al (2017) Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31(7):1229–1238CrossRefPubMed
21.
go back to reference Jimenez-Gallo D et al (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401CrossRefPubMedPubMedCentral Jimenez-Gallo D et al (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401CrossRefPubMedPubMedCentral
22.
go back to reference Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 79(2):345–352CrossRefPubMed Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 79(2):345–352CrossRefPubMed
23.
go back to reference Mora-Ruiz MD et al (2019) Role of interleukin-17 in acute myocardial infarction. Mol Immunol 107:71–78CrossRefPubMed Mora-Ruiz MD et al (2019) Role of interleukin-17 in acute myocardial infarction. Mol Immunol 107:71–78CrossRefPubMed
24.
go back to reference Zhang L et al (2019) IL-17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPKalpha/p38MAPK/ERK1/2 signal pathway in mice. Mol Immunol 105:240–250CrossRefPubMed Zhang L et al (2019) IL-17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPKalpha/p38MAPK/ERK1/2 signal pathway in mice. Mol Immunol 105:240–250CrossRefPubMed
25.
go back to reference Reddy S et al (2020) Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol 156(1):65–71CrossRefPubMed Reddy S et al (2020) Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol 156(1):65–71CrossRefPubMed
26.
go back to reference Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefPubMed Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefPubMed
27.
go back to reference Reddy S, Strunk A, Garg A (2019) All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol 81(4):937–942CrossRefPubMed Reddy S, Strunk A, Garg A (2019) All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol 81(4):937–942CrossRefPubMed
Metadata
Title
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study
Authors
Khalaf Kridin
Kailyn Valido
Jeffrey M. Cohen
Arnon D. Cohen
Publication date
23-07-2022
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 3/2023
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-022-02369-5

Other articles of this Issue 3/2023

Archives of Dermatological Research 3/2023 Go to the issue